Skip to content

Clinical study on the effect of oral microbiota on the efficacy of neoadjuvant chemoradiotherapy in locally advanced resectable esophageal squamous cell carcinoma

Clinical study on the effect of oral microbiota on the efficacy of neoadjuvant chemoradiotherapy in locally advanced resectable esophageal squamous cell carcinoma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097912
Enrollment
Unknown
Registered
2025-02-27
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Interventions

Treatment Group:Tooth Cleaning

Sponsors

West china hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Participants must meet all of the following inclusion criteria in order to be included in this study. (1) When signing the informed consent form, the age should be between 18 years old (inclusive) and 75 years old (inclusive); (2) Clinically diagnosed locally advanced resectable esophageal cancer; (3) Plan to receive neoadjuvant chemoradiotherapy and have the intention of surgical resection; (4) Agree to undergo dental cleaning intervention before neoadjuvant chemoradiotherapy.

Exclusion criteria

Exclusion criteria: If a subject meets any of the following criteria, they cannot be enrolled in this study. (1) Esophageal cancer patients with a history of radiotherapy, chemotherapy, or surgical treatment; (2) There are serious oral diseases, such as active periodontal disease, oral infections, etc., which are not suitable for dental cleaning intervention; (3) There are serious systemic diseases such as cardiovascular disease, renal dysfunction, liver dysfunction, etc., which affect the reliability of research results; (4) The researchers believe that participants should not participate in other situations of this study.

Design outcomes

Primary

MeasureTime frame
pathologic complete response rate;

Secondary

MeasureTime frame
Immune indicators, including white blood cell count, C-reactive protein (CRP), and cytokine levels (such as IL-6, TNF - a, etc.);

Countries

China

Contacts

Public ContactYong Yuan

Department of thoracic surgery, West china hospital, Sichuan University

yongyuan@scu.edu.cn+86 189 8060 6739

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026